{"version":"1.2.0","chapters":[{"startTime":0,"title":"Introduction"},{"startTime":94,"title":"Are we reaching the limits of human longevity? "},{"startTime":133,"title":"Are weight-loss drugs a bubble or a structural shift? "},{"startTime":253,"title":"How the White House\u2013pharma deal changes drug pricing "},{"startTime":418,"title":"Who wins and loses in a world with fewer illnesses? "},{"startTime":490,"title":" Why longevity is becoming a macroeconomic risk "},{"startTime":628,"title":"Who holds power in an AI-driven pharmaceutical world? "},{"startTime":747,"title":" How to maintain trust when AI outperforms humans in diagnostics "},{"startTime":831,"title":" How AI is transforming preventative medicine "},{"startTime":987,"title":" Will data expertise surpass clinical expertise?"},{"startTime":1055,"title":"Who is accountable when AI influences medical decisions?"},{"startTime":1137,"title":"Why regulation must catch up with rapid AI innovation"},{"startTime":1247,"title":" Will AI-driven healthcare widen inequality?"},{"startTime":1359,"title":"How demographics and geopolitics shape healthcare tailwinds"},{"startTime":1436,"title":"How leaders build conviction in a VUCA healthcare landscape"},{"startTime":1522,"title":"The next frontier in personalised and preventative medicine"}]}